THERAPY FOR THE TREATMENT OF CANCER
The present invention is directed to regimens for administering one or more Antibody-Based Molecules that bind PD-1 or PD-L1, and LAG-3 (e.g, a PD-1×LAG-3 bispecific molecule) alone, or in combination with an Antibody-Based Molecule that binds a Tumor Antigen (TA) for the treatment of cancer. The in...
Saved in:
Main Authors | , , , , , , |
---|---|
Format | Patent |
Language | English French German |
Published |
10.01.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present invention is directed to regimens for administering one or more Antibody-Based Molecules that bind PD-1 or PD-L1, and LAG-3 (e.g, a PD-1×LAG-3 bispecific molecule) alone, or in combination with an Antibody-Based Molecule that binds a Tumor Antigen (TA) for the treatment of cancer. The invention particularly concerns the use of such regimens in conjunction with PD-1×LAG-3 bispecific molecules. The invention is directed to the use of such molecules, and to the use of pharmaceutical compositions and pharmaceutical kits that contain such molecules and that facilitate the use of such dosing regimens in the treatment of cancer. |
---|---|
Bibliography: | Application Number: EP20200906153 |